Chimera Research Group

previous arrow
next arrow
Slider

May 22nd Biotech Update

Nothing is ever clean in the sector (at least over the past couple of years).  What could have been a nice move to higher highs has been put on pause. This is not to say that is off the table or that the sector has broken down as that is not the case at all.  […]

April 21st Biotech Update

It has been a little wild in the sector in terms of news (MFN pricing executive order) but if you take a step back and look at the chart, it does not look nearly as bad as it sounded when the announcement happened.  Just imagine that you know nothing of the news and look at […]

April 5th Biotech Update

So, we are at the area where we have bounced off of what might be a major bottom and have basically closed a gap to the upside.  The market is overbought and that is likely the case for the sector as well.  All of this being said, it seem like a natural place for a […]

Mailing List

Introduction

Overview

Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press

Slider

Log In

JoinLost Password?